4.29
+0.24(+5.93%)
Currency In USD
| Previous Close | 4.05 |
| Open | 4.05 |
| Day High | 4.6 |
| Day Low | 4.03 |
| 52-Week High | 91.25 |
| 52-Week Low | 3.13 |
| Volume | 283,340 |
| Average Volume | 313,759 |
| Market Cap | 5.19M |
| PE | -0.09 |
| EPS | -49.75 |
| Moving Average 50 Days | 7.34 |
| Moving Average 200 Days | 14.18 |
| Change | 0.24 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.24 as of January 14, 2026 at a share price of $4.29. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $1.89 as of January 14, 2026 at a share price of $4.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
GlobeNewswire Inc.
12 hours ago
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
GlobeNewswire Inc.
Jan 12, 2026 1:36 PM GMT
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“M
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
GlobeNewswire Inc.
Dec 17, 2025 1:31 PM GMT
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal